Does the media favor BCYC or MGTX?

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 2 articles in the media. Bicycle Therapeutics' average media sentiment score of 1.75 beat MeiraGTx's score of 1.61 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer SVRA or BCYC?

In the previous week, Savara had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 5 mentions for Savara and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.75 beat Savara's score of 1.06 indicating that Bicycle Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BCYC or ORIC?

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.75 beat Oric Pharmaceuticals' score of 0.72 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oric Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCYC or SDGR?

In the previous week, Schrodinger had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.75 beat Schrodinger's score of 1.26 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCYC or WVE?

In the previous week, WAVE Life Sciences had 6 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 8 mentions for WAVE Life Sciences and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.75 beat WAVE Life Sciences' score of 0.91 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive WAVE Life Sciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bicycle Therapeutics (BCYC) Competitors

$3.87 -0.29 (-6.97%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.88 +0.00 (+0.13%)

As of 07/24/2026 07:34 PM Eastern

Compare

BCYC vs. MGTX, SVRA, ORIC, SDGR, and WVE

Should you buy Bicycle Therapeutics stock or one of its competitors? MarketBeat compares Bicycle Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicycle Therapeutics include MeiraGTx (MGTX), Savara (SVRA), Oric Pharmaceuticals (ORIC), Schrodinger (SDGR), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

How does Bicycle Therapeutics compare to MeiraGTx?

Bicycle Therapeutics (NASDAQ:BCYC) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

MeiraGTx has higher revenue and earnings than Bicycle Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.71	-$218.96M	-$3.15	N/A
MeiraGTx	$79.76M	13.67	-$114.20M	-$1.48	N/A

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bicycle Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

MeiraGTx has a net margin of -151.12% compared to Bicycle Therapeutics' net margin of -344.95%. MeiraGTx's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
MeiraGTx	-151.12%	N/A	-54.96%

Bicycle Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 261.76%. MeiraGTx has a consensus price target of $26.00, indicating a potential upside of 120.90%. Given Bicycle Therapeutics' higher possible upside, equities research analysts plainly believe Bicycle Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 2 articles in the media. Bicycle Therapeutics' average media sentiment score of 1.75 beat MeiraGTx's score of 1.61 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

MeiraGTx beats Bicycle Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

In the previous week, Savara had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 5 mentions for Savara and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.75 beat Savara's score of 1.06 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Savara currently has a consensus target price of $10.14, suggesting a potential upside of 84.08%. Bicycle Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 261.76%. Given Bicycle Therapeutics' higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Savara has higher earnings, but lower revenue than Bicycle Therapeutics. Savara is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Bicycle Therapeutics	$72.86M	3.71	-$218.96M	-$3.15	N/A

Savara has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

87.9% of Savara shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Savara has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

Summary

Savara and Bicycle Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Oric Pharmaceuticals?

Bicycle Therapeutics (NASDAQ:BCYC) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Bicycle Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 261.76%. Oric Pharmaceuticals has a consensus target price of $19.27, indicating a potential upside of 59.28%. Given Bicycle Therapeutics' higher possible upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oric Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Oric Pharmaceuticals' return on equity of -35.33% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Bicycle Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.75 beat Oric Pharmaceuticals' score of 0.72 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has lower revenue, but higher earnings than Bicycle Therapeutics. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.71	-$218.96M	-$3.15	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Summary

Oric Pharmaceuticals beats Bicycle Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Schrodinger?

Bicycle Therapeutics (NASDAQ:BCYC) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Schrodinger has higher revenue and earnings than Bicycle Therapeutics. Schrodinger is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.71	-$218.96M	-$3.15	N/A
Schrodinger	$254.91M	4.34	-$103.26M	-$1.41	N/A

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 10.1% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bicycle Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Schrodinger has a net margin of -40.61% compared to Bicycle Therapeutics' net margin of -344.95%. Schrodinger's return on equity of -30.85% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Schrodinger	-40.61%	-30.85%	-15.32%

In the previous week, Schrodinger had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.75 beat Schrodinger's score of 1.26 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicycle Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 261.76%. Schrodinger has a consensus price target of $20.25, indicating a potential upside of 35.27%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Schrodinger beats Bicycle Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Bicycle Therapeutics (NASDAQ:BCYC) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Bicycle Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 261.76%. WAVE Life Sciences has a consensus target price of $26.41, indicating a potential upside of 354.59%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

WAVE Life Sciences has lower revenue, but higher earnings than Bicycle Therapeutics. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.71	-$218.96M	-$3.15	N/A
WAVE Life Sciences	$42.73M	26.16	-$204.38M	-$1.06	N/A

Bicycle Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, suggesting that its share price is 229% less volatile than the broader market.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

WAVE Life Sciences has a net margin of -255.70% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

In the previous week, WAVE Life Sciences had 6 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 8 mentions for WAVE Life Sciences and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.75 beat WAVE Life Sciences' score of 0.91 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
WAVE Life Sciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

WAVE Life Sciences beats Bicycle Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCYC vs. The Competition

Export

Metric	Bicycle Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.42M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.23	21.48	27.14	23.64
Price / Sales	3.71	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.44	7.88	10.28	6.07
Net Income	-$218.96M	$23.86M	$3.60B	$331.99M
7 Day Performance	-8.08%	-3.82%	-1.27%	-0.63%
1 Month Performance	-3.49%	-2.61%	-0.37%	-2.00%
1 Year Performance	-55.52%	32.79%	18.30%	13.62%

Bicycle Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCYC Bicycle Therapeutics	3.0228 of 5 stars	$3.87 -7.0%	$14.00 +261.8%	-55.0%	$290.42M	$72.86M	N/A	240	News Coverage Positive News
MGTX MeiraGTx	3.9969 of 5 stars	$12.39 +1.4%	$26.00 +109.9%	+41.6%	$1.15B	$81.39M	N/A	300	Gap Down
SVRA Savara	1.8268 of 5 stars	$5.58 +1.7%	$10.14 +81.7%	+116.1%	$1.14B	N/A	N/A	20	News Coverage Positive News
ORIC Oric Pharmaceuticals	2.3603 of 5 stars	$10.96 +5.1%	$19.27 +75.9%	+3.2%	$1.13B	N/A	N/A	80	News Coverage Analyst Upgrade
SDGR Schrodinger	2.3319 of 5 stars	$15.23 +1.6%	$20.25 +32.9%	-33.4%	$1.13B	$255.87M	N/A	790	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCYC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. MGTX, SVRA, ORIC, SDGR, and WVE

How does Bicycle Therapeutics compare to MeiraGTx?

Summary

How does Bicycle Therapeutics compare to Savara?

Summary

How does Bicycle Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Bicycle Therapeutics compare to Schrodinger?

Summary

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. MGTX, SVRA, ORIC, SDGR, and WVE

How does Bicycle Therapeutics compare to MeiraGTx?

Which has better earnings & valuation, BCYC or MGTX?

Do institutionals and insiders have more ownership in BCYC or MGTX?

Which has more volatility & risk, BCYC or MGTX?

Is BCYC or MGTX more profitable?

Do analysts rate BCYC or MGTX?

Does the media favor BCYC or MGTX?

Summary

How does Bicycle Therapeutics compare to Savara?

Does the media prefer SVRA or BCYC?

Do analysts rate SVRA or BCYC?

Which has better valuation and earnings, SVRA or BCYC?

Which has more volatility and risk, SVRA or BCYC?

Do institutionals & insiders have more ownership in SVRA or BCYC?

Is SVRA or BCYC more profitable?

Summary

How does Bicycle Therapeutics compare to Oric Pharmaceuticals?

Do analysts rate BCYC or ORIC?

Do insiders and institutionals believe in BCYC or ORIC?

Is BCYC or ORIC more profitable?

Which has more volatility & risk, BCYC or ORIC?

Does the media prefer BCYC or ORIC?

Which has preferable earnings and valuation, BCYC or ORIC?

Summary

How does Bicycle Therapeutics compare to Schrodinger?

Which has stronger earnings & valuation, BCYC or SDGR?

Do institutionals & insiders believe in BCYC or SDGR?

Which has more volatility and risk, BCYC or SDGR?

Is BCYC or SDGR more profitable?

Does the media prefer BCYC or SDGR?

Do analysts recommend BCYC or SDGR?

Summary

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Do analysts prefer BCYC or WVE?

Which has stronger earnings and valuation, BCYC or WVE?

Which has more risk and volatility, BCYC or WVE?

Do institutionals and insiders believe in BCYC or WVE?

Is BCYC or WVE more profitable?

Does the media prefer BCYC or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools